Martin Joyce, CFO and executive vice president of BioSphere Medical, Inc., presented yesterday (June 17th) at Capstone Investment’s Second Annual Investor Conference in Milwaukee, Wisconsin.
BioSphere Medical’s main focus is the development of non-invasive diagnosis and treatment methods of uterine fibroids, using a technique known as uterine fibroid embolization. Uterine fibroids are muscular tumors that form in the wall of the uterus, and are almost always benign (non-cancerous). These often symptomless tumors most commonly affect women approximately forty to fifty years of age.
At Tuesday’s conference, Mr. Joyce spoke about his company’s weapon against uterine fibroids, Embosphere®, noting the progress that has been made with the product. He compared it to another leading treatment in this statement: “In the 2008 edition of the Journal of Vascular and Interventional Radiology, a study was featured in which Embosphere® Microspheres significantly outperformed Boston Scientific’s Contour SE™ PVA embolic. There was also a lower incidence of treatment failure.”
The announcement works toward boosting the company’s already growing acceptance as a leader in treating this particular type of tumor. While the affliction does not normally lead to cancer, left unchecked it can result in disfigurement and the necessity for performing hysterectomies on affected patients. BioSphere’s treatment will hopefully play an instrumental role in reducing the likelihood of such situations.
Let us hear your thoughts below:
